![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/08/22/2934041/0/en/Lipella-Pharmaceuticals-Launches-Innovative-Registry-to-Advance-Oral-Lichen-Planus-Research.html
https://www.globenewswire.com/news-release/2024/08/12/2928175/0/en/Lipella-Pharmaceuticals-Doses-First-Two-Patients-in-Phase-2a-Oral-Lichen-Planus-Clinical-Trial.html
https://www.globenewswire.com/news-release/2024/08/01/2923218/0/en/Lipella-Pharmaceuticals-Announces-Closing-of-1-28-Million-Registered-Direct-Offering-of-Common-Stock-Priced-At-the-Market-Under-Nasdaq-Rules.html
https://www.globenewswire.com/news-release/2024/08/01/2922718/0/en/Lipella-Pharmaceuticals-Announces-1-28-Million-Registered-Direct-Offering-of-Common-Stock-Priced-At-the-Market-Under-Nasdaq-Rules.html
https://www.globenewswire.com/news-release/2024/07/29/2920081/0/en/Lipella-Pharmaceuticals-Initiates-Phase-2a-Trial-for-LP-310-in-Oral-Lichen-Planus-Enrolls-First-Patients.html
https://www.globenewswire.com/news-release/2024/05/31/2891477/0/en/Lipella-Pharmaceuticals-Announces-Completion-of-Site-Initiation-Visit-for-Phase-2a-Trial-of-LP-310-in-Oral-Lichen-Planus.html
https://www.globenewswire.com/news-release/2024/05/29/2889786/0/en/Lipella-Pharmaceuticals-Announces-Abstract-Publication-at-2024-American-Society-of-Clinical-Oncology-ASCO-Annual-Meeting.html
https://www.globenewswire.com/news-release/2024/05/21/2885517/0/en/Following-Guidance-from-U-S-Food-Drug-Administration-in-Type-C-Meeting-Lipella-Pharmaceuticals-to-Advance-Lead-Product-Candidate-to-Phase-2b.html
https://www.globenewswire.com/news-release/2024/04/17/2864435/0/en/Lipella-Pharmaceuticals-Expands-its-Advisory-Board-to-Include-Oncology-Expertise.html
https://www.globenewswire.com/news-release/2024/04/05/2858476/0/en/Lipella-Pharmaceuticals-to-Publish-Abstract-Detailing-Compelling-Preclinical-Support-for-New-Product-Candidate-at-ASCO-2024.html